These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation and chronic kidney disease. Bhatia HS; Bailey J; Unlu O; Hoffman K; Kim RJ Pacing Clin Electrophysiol; 2019 Nov; 42(11):1463-1470. PubMed ID: 31599969 [TBL] [Abstract][Full Text] [Related]
23. Comparative effectiveness and safety of oral anticoagulants for atrial fibrillation: A retrospective cohort study. Holbrook A; Morrow R; Lee AYY; Foster G; Pullenyegum E J Popul Ther Clin Pharmacol; 2020 Apr; 27(2):e28-e44. PubMed ID: 32320170 [TBL] [Abstract][Full Text] [Related]
24. Outcomes of Cardiac Catheterization in Patients With Atrial Fibrillation on Anticoagulation in Contemporary in Practice: An Analysis of the ORBIT II Registry. Sherwood MW; Piccini JP; Holmes DN; Pieper KS; Steinberg BA; Fonarow GC; Allen LA; Naccarelli GV; Kowey PR; Gersh BJ; Mahaffey KW; Singer DE; Ansell JE; Freeman JV; Chan PS; Reiffel JA; Blanco R; Peterson ED; Rao SV Circ Cardiovasc Interv; 2020 May; 13(5):e008274. PubMed ID: 32408815 [TBL] [Abstract][Full Text] [Related]
25. Management of hemorrhage with the target-specific oral anticoagulants. Pluym M; Howell G Hosp Pract (1995); 2014 Aug; 42(3):75-83. PubMed ID: 25255409 [TBL] [Abstract][Full Text] [Related]
26. Direct oral anticoagulants and warfarin in patients with cirrhosis: a comparison of outcomes. Davis KA; Joseph J; Nisly SA J Thromb Thrombolysis; 2020 Aug; 50(2):457-461. PubMed ID: 31915998 [TBL] [Abstract][Full Text] [Related]
27. Preclinical and clinical data for factor Xa and "universal" reversal agents. Milling TJ; Kaatz S Am J Emerg Med; 2016 Nov; 34(11S):39-45. PubMed ID: 27697443 [TBL] [Abstract][Full Text] [Related]
28. A Phase II, double-blind, randomized, parallel group, dose-finding study of the safety and tolerability of darexaban compared with warfarin in patients with non-valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL-2). Lip GY; Halperin JL; Petersen P; Rodgers GM; Pall D; Renfurm RW J Thromb Haemost; 2015 Aug; 13(8):1405-13. PubMed ID: 26052866 [TBL] [Abstract][Full Text] [Related]
29. To Bleed or Not to Bleed: That is the Question. The Side Effects of Apixaban. Ciccone MM; Zito A; Devito F; Maiello M; Palmiero P Curr Drug Targets; 2018; 19(6):581-584. PubMed ID: 26424386 [TBL] [Abstract][Full Text] [Related]
30. A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens. Providência R; Grove EL; Husted S; Barra S; Boveda S; Morais J Thromb Res; 2014 Dec; 134(6):1253-64. PubMed ID: 25457584 [TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data. Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411 [TBL] [Abstract][Full Text] [Related]
32. Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists. Di Nisio M; Raskob G; Büller HR; Grosso MA; Zhang G; Winters SM; Cohen A Thromb Haemost; 2017 Apr; 117(4):784-793. PubMed ID: 28151543 [TBL] [Abstract][Full Text] [Related]
33. Economic evaluation of prescribing conventional and newer oral anticoagulants in older adults. Hasan SS; Kow CS; Curley LE; Baines DL; Babar ZU Expert Rev Pharmacoecon Outcomes Res; 2018 Aug; 18(4):371-377. PubMed ID: 29741099 [TBL] [Abstract][Full Text] [Related]
34. Recommendations for the use of andexanet alfa in the management of bleeding in patients on oral factor Xa inhibitors in Switzerland: Guideline from the Working Party Hemostasis of the Swiss Society of Hematology. Angelillo-Scherrer A; Casini A; Studt JD; Gerber B; Alberio LA; Fontana P Swiss Med Wkly; 2023 Jul; 153():40113. PubMed ID: 37499160 [TBL] [Abstract][Full Text] [Related]
36. Safety and Efficacy of Apixaban Versus Warfarin in Patients With Advanced Chronic Kidney Disease. Schafer JH; Casey AL; Dupre KA; Staubes BA Ann Pharmacother; 2018 Nov; 52(11):1078-1084. PubMed ID: 29871510 [TBL] [Abstract][Full Text] [Related]
37. Comparative Effectiveness and Safety of Direct-acting Oral Anticoagulants and Warfarin in Patients with Venous Thromboembolism and Active Cancer: An Observational Analysis. Dawwas GK; Dietrich E; Smith SM; Davis K; Park H Clin Ther; 2020 Sep; 42(9):e161-e176. PubMed ID: 32768247 [TBL] [Abstract][Full Text] [Related]
38. Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism - The SWAN Study. Hendriks T; McGregor S; Rakesh S; Robinson J; Ho KM; Baker R PLoS One; 2020; 15(6):e0234048. PubMed ID: 32497116 [TBL] [Abstract][Full Text] [Related]
39. Oral anticoagulants and status of antidotes for the reversal of bleeding risk. Ebright J; Mousa SA Clin Appl Thromb Hemost; 2015 Mar; 21(2):105-14. PubMed ID: 25115762 [TBL] [Abstract][Full Text] [Related]
40. The safety of oral anticoagulants registry (SOAR): A national, ED-based study of the evaluation and management of bleeding and bleeding concerns due to the use of oral anticoagulants. Pollack CV; Peacock WF; Bernstein RA; Clark CL; Douketis J; Fermann GJ; Fiore GJ; Frost A; Jahromi B; Johnson C; Merli G; Silber S; Villines TC; Fanikos J; Am J Emerg Med; 2020 Jun; 38(6):1163-1170. PubMed ID: 32014375 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]